Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27


A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.

Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Pignon JM, Corm S, Banos A, Mounier C, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouadallah K, Amorin S, Garidi R, Voillat L, Joly B, Celigny PS, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Le Gouill S, Callanan MB; Lymphoma Study Association.

Haematologica. 2019 Jan;104(1):138-146. doi: 10.3324/haematol.2018.191429. Epub 2018 Aug 31.


Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.

Gyan E, Sonet A, Brice P, Anglaret B, Laribi K, Fruchart C, Tilly H, Araujo C, Soubeyran P, Gonzalez H, Morineau N, Nicolas-Virelizier E, Ghesquières H, Salles B, Bouabdallah R, Orfeuvre H, Fahri J, Couturier O, Xerri L, Feugier P; Lymphoma Study Association (LYSA).

Br J Haematol. 2018 Oct;183(1):76-86. doi: 10.1111/bjh.15513. Epub 2018 Aug 16.


Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.

Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Gouilleux-Gruart V, Barbet J, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P.

Lancet Haematol. 2017 Jan;4(1):e35-e45. doi: 10.1016/S2352-3026(16)30168-5. Epub 2016 Dec 8.


Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program.

Damaj G, Malard F, Hulin C, Caillot D, Garidi R, Royer B, Marit G, Stoppa AM, Banos A, Morineau N, Moreau P, Fitoussi O, Tiab M, Moreau P.

Leuk Lymphoma. 2012 Apr;53(4):632-4. doi: 10.3109/10428194.2011.622422. Epub 2011 Nov 25.


18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group.

Cahu X, Bodet-Milin C, Brissot E, Maisonneuve H, Houot R, Morineau N, Solal-Celigny P, Godmer P, Gastinne T, Moreau P, Moreau A, Lamy T, Kraber-Bodere F, Le Gouill S.

Ann Oncol. 2011 Mar;22(3):705-11. doi: 10.1093/annonc/mdq415. Epub 2010 Aug 25.


Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.

Bodet-Milin C, Touzeau C, Leux C, Sahin M, Moreau A, Maisonneuve H, Morineau N, Jardel H, Moreau P, Gallazini-Crépin C, Gries P, Gressin R, Harousseau JL, Mohty M, Moreau P, Kraeber-Bodere F, Le Gouill S.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1633-42. doi: 10.1007/s00259-010-1469-2. Epub 2010 Apr 29.


[Paclitaxel-induced lupus].

Lortholary A, Cary-Ten Have Dallinga M, El Kouri C, Morineau N, Ramée JF.

Presse Med. 2007 Sep;36(9 Pt 1):1207-8. Epub 2007 May 22. French.


Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required.

Vigouroux S, Morin O, Moreau P, Méchinaud F, Morineau N, Mahé B, Chevallier P, Guillaume T, Dubruille V, Harousseau JL, Milpied N.

Clin Infect Dis. 2005 Feb 15;40(4):e35-7. Epub 2005 Jan 25.


Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma.

Blin N, Morineau N, Gaillard F, Morin O, Milpied N, Harousseau JL, Moreau P.

Leuk Lymphoma. 2004 Oct;45(10):2161-3.


Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma.

Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N, Harousseau JL, Bataille R.

Haematologica. 2004 May;89(5):547-51.


Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma.

Moreau P, Misbahi R, Milpied N, Morineau N, Mahé B, Vigier M, Rapp MJ, Bataille R, Harousseau JL.

Leukemia. 2002 Sep;16(9):1838-43.


Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy.

Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, Bataille R, Avet-Loiseau H; Intergroupe Francophone du Myélome.

Blood. 2002 Sep 1;100(5):1579-83.


Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy.

Vigouroux S, Milpied N, Andrieu JM, Colonna P, Ifrah N, Colombat P, Desablens B, Abgrall JF, Casassus P, Guilhot F, Briere J, Le Mevel A, Moreau P, Mechinaud F, Mahe B, Morineau N, Vigier M, Rapp MJ, Harousseau JL.

Bone Marrow Transplant. 2002 May;29(10):833-42.


Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.

Spisek R, Chevallier P, Morineau N, Milpied N, Avet-Loiseau H, Harousseau JL, Meflah K, Gregoire M.

Cancer Res. 2002 May 15;62(10):2861-8.


[Autologous peripheral blood selected CD34+ cell transplantation in the treatment of multiple myeloma].

Tang X, Morineau N, Milpied N, Moreau P, Bataille R, Harousseau JL.

Zhonghua Xue Ye Xue Za Zhi. 2001 Jul;22(7):370-3. Chinese.


Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants.

Ninin E, Milpied N, Moreau P, André-Richet B, Morineau N, Mahé B, Vigier M, Imbert BM, Morin O, Harousseau JL, Richet H.

Clin Infect Dis. 2001 Jul 1;33(1):41-7. Epub 2001 May 23.


Lack of benefit of CD34+ cell selected over non-selected peripheral blood stem cell transplantation in multiple myeloma: results of a single center study.

Morineau N, Tang XW, Moreau P, Milpied N, Mahé B, Bataille R, Harousseau JL.

Leukemia. 2000 Oct;14(10):1815-20.


Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome.

Avet-Loiseau H, Li JY, Morineau N, Facon T, Brigaudeau C, Harousseau JL, Grosbois B, Bataille R.

Blood. 1999 Oct 15;94(8):2583-9.


P53 deletion is not a frequent event in multiple myeloma.

Avet-Loiseau H, Li JY, Godon C, Morineau N, Daviet A, Harousseau JL, Facon T, Bataille R.

Br J Haematol. 1999 Sep;106(3):717-9.


[Pseudallescheria boydii osteoarthritis in a patient with acute lymphoblastic leukemia: a case report].

Le Gouill SL, Morineau N, Miégeville M, Milpied N, Harousseau JL, Moreau P.

Rev Med Interne. 1999 May;20(5):434-8. French.


High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization.

Avet-Loiseau H, Brigaudeau C, Morineau N, Talmant P, Laï JL, Daviet A, Li JY, Praloran V, Rapp MJ, Harousseau JL, Facon T, Bataille R.

Genes Chromosomes Cancer. 1999 Jan;24(1):9-15.


High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.

Avet-Loiseau H, Li JY, Facon T, Brigaudeau C, Morineau N, Maloisel F, Rapp MJ, Talmant P, Trimoreau F, Jaccard A, Harousseau JL, Bataille R.

Cancer Res. 1998 Dec 15;58(24):5640-5.


High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience.

Milpied N, Gaillard F, Moreau P, Mahé B, Souchet J, Rapp MJ, Bulabois CE, Morineau N, Harousseau JL.

Bone Marrow Transplant. 1998 Oct;22(7):645-50.


Early intensive therapy with autologous stem cell transplantation in high-risk Hodgkin's disease: long-term follow-up in 35 cases.

Moreau P, Milpied N, Rapp MJ, Moreau A, Bourdin S, Mahe MA, Dupas B, Le Tortorec S, Hamidou M, Maisoneuve H, Mahe B, Bulabois CE, Morineau N, Jardel H, Harousseau JL.

Leuk Lymphoma. 1998 Jul;30(3-4):313-24.


Supplemental Content

Loading ...
Support Center